Bulk clindamycin phosphate will be first product manufactured at firm's new manufacturing facility in Haverhill, U.K. Firm expects the new operations to generate sales in excess of $ 11 mil. in 1988, with 85% of the revenue from exports. Construction of the facility was supported by almost $ 700,000 in grant support from the U.K. Department of Trade and Industry.
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.